Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech success, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (100)	10/23/2002 5:35:57 PM
From: keokalani'nui	Respond to of 117

Vertex Pharmaceuticals Provides Update on GW433908 (908; VX-175) Clinical Development Program Wednesday October 23, 4:01 pm ET CAMBRIDGE, Mass., Oct. 23 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) today provided an update on the Phase III clinical program on GW433908 (also known as 908 or VX-175), the investigational HIV protease inhibitor co-discovered with GlaxoSmithKline. GSK has conducted a preliminary 24-week interim analysis of the CONTEXT study (also known as 30003), the third of three pivotal studies of 908. The interim analysis indicates that the 908 study arms have met their study endpoints at 24 weeks. In addition, GSK has now conducted preliminary 48-week analyses of two other pivotal studies of 908, the NEAT (also known as 30001) and SOLO (also known as 30002) studies. These analyses indicate that the 908 arms in each of these studies have met their study endpoints at 48 weeks. More than 1,100 people are participating in the Phase III clinical program, which is designed to test the safety and efficacy of 908. GlaxoSmithKline is now preparing regulatory submissions for market approval of 908 in the United States and the European Union. Once approved, 908 will be marketed by GSK and co-promoted by Vertex Pharmaceuticals.